P2.4 the Influence of Antihypertensive Treatment on Arterial Stiffness, Shear Stress and Activity of Chosen Matrix Metalloproteinases

Pizon, T.; Rajzer, Marek; Rojek, Marta; Czarnecka, Danuta

doi:10.1016/j.artres.2015.10.211

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is difficult to propose possible clinical application of tissue inhibitors of metalloproteinases (TIMPs) in treatment, since some reports reveal that TIMP-2 are capable of blocking the vasodilator effect of MMP-2 in small blood vessels, which additionally would potentiate pathological mechanism observed in preeclampsia [ 24 – 27 ]. Moreover, it should be underlined that this vasodilator effect is even more pronounced in pregnancies complicated by preeclampsia in comparison to healthy pregnancies and reaction in nonpregnant women [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia

Laskowska

2017

BioMed Research International

View full text Add to dashboard Cite

Objective The aim of this study was to determine whether maternal serum matrix metalloproteinases 2, 3, 9, and 13 levels differ in early- and late-onset preeclampsia and uncomplicated pregnancies. Patients and Methods The study was carried out in 125 pregnant women (29 with early-onset preeclampsia; 31 preeclamptic patients with late-onset preeclampsia; and 65 healthy pregnant controls). Levels of MMP-2, MMP-3, MMP-9, and MMP-13 were measured in the maternal serum using an enzyme-linked immunosorbent assay. Results Maternal serum MMP-2 levels in both the groups of preeclamptic women were significantly higher than those in the controls. Levels of MMP-3 were significantly higher in preeclamptic patients with early-onset disease; however, the MMP-3 levels in patients with late-onset preeclampsia were similar to those observed in the control subjects. MMP-9 levels were lower whereas the levels of MMP-13 were higher in both preeclamptic groups of pregnant women than in the healthy controls, but these differences were statistically insignificant. Conclusions One important finding of the present study was that MMP-3 appears to be involved solely in early-onset preeclampsia, but not in late-onset preeclampsia. Higher levels of MMP-2 and MMP-13 and lower levels of MMP-9 seem to be related to both early- and late-onset severe preeclampsia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Despite initially promising signals about possible use of MMPs inhibitors, it is hard to clearly determine their role in medical treatment [ 24 – 27 ]. Studies carried out on animals models show that the use of MMPs inhibitors in cancer treatment did not bring expected results [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia

Laskowska

2017

BioMed Research International

View full text Add to dashboard Cite

show abstract

Section: Implications Of the Present And Previous Reviewsmentioning

confidence: 99%

“…53 In other studies of individuals with hypertension under an antihypertensive therapeutic regimen, a decrease in arterial stiffness has been shown associated with a decrease in MMP and an increase in TIMP-1. 54 Taking all of the above into account, a myriad of proinflammatory cytokines and MMPs have been identified as potential effectors of accelerated vascular ageing associated with AID. Therefore, this field of study is likely to be a viable way to result in clinical application.…”

Section: Autoimmunity Autoimmunity Autoimmunitymentioning

confidence: 99%

Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis

Santos-Moreno¹,

Burgos-Angulo

Martínez-Ceballos

et al. 2021

RMD Open

View full text Add to dashboard Cite

Currently, traditional and non-traditional risk factors for cardiovascular disease have been established. The first group includes age, which constitutes one of the most important factors in the development of chronic diseases. The second group includes inflammation, the pathophysiology of which contributes to an accelerated process of vascular remodelling and atherogenesis in autoimmune diseases. Indeed, the term inflammaging has been used to refer to the inflammatory origin of ageing, explicitly due to the chronic inflammatory process associated with age (in healthy individuals). Taking this into account, it can be inferred that people with autoimmune diseases are likely to have an early acceleration of vascular ageing (vascular stiffness) as evidenced in the alteration of non-invasive cardiovascular tests such as pulse wave velocity. Thus, an association is created between autoimmunity and high morbidity and mortality rates caused by cardiovascular disease in this population group. The beneficial impact of the treatments for rheumatoid arthritis at the cardiovascular level has been reported, opening new opportunities for pharmacotherapy.

show abstract

P2.4 the Influence of Antihypertensive Treatment on Arterial Stiffness, Shear Stress and Activity of Chosen Matrix Metalloproteinases

Cited by 2 publications

References 0 publications

Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia

Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia

Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis

Contact Info

Product

Resources

About